GlassScriptPhysician profile
Mallory Searcy
NPI 1215600424
$4,304.66
in general payments reported to CMS, 2019-2025
29 companies · $265 in 2025
The $265 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $330 · 2022: $1,250 · 2023: $990 · 2024: $1,470 · 2025: $265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,641 · Education: $84.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,640.76 |
| Education | $84.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,295.02 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Corcept Therapeutics | $624.69 | 2021-2025 | Korlym |
| Medtronic, INC. | $400.80 | 2023-2024 | Minimed 780g, Minimed 770g |
| Sanofi-Aventis U.S. LLC | $347.89 | 2021-2025 | |
| Amgen INC. | $242.77 | 2024-2025 | Evenity, Prolia, Tepezza |
| Bayer Healthcare Pharmaceuticals INC. | $205.85 | 2022-2024 | |
| Mannkind Corporation | $171.26 | 2021-2024 | Afrezza |
| Lilly USA, LLC | $163.29 | 2021-2024 | Jardiance, Baqsimi, Mounjaro |
| Xeris Pharmaceuticals, INC. | $117.44 | 2021-2024 | Gvoke Hypopen, Recorlev |
| Abbvie INC. | $99.66 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $75.71 | 2021-2024 | Lokelma |
| Tandem Diabetes Care, INC. | $72.39 | 2021-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Insulet Corporation | $69.00 | 2024 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.62 | 2021-2023 | Jardiance |
| Alexion Pharmaceuticals, INC. | $49.61 | 2023-2024 | Strensiq |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascendis Pharma Endocrinology INC | $39.81 | 2023-2024 | |
| Amneal Pharmaceuticals LLC | $36.51 | 2022-2024 | Unithroid |
| Dexcom, INC. | $30.23 | 2022-2023 | Dexcom G6 Transmitter |
| Amryt Pharma Holdings LTD | $25.41 | 2023 | Myalept |
| Cequr Corporation | $22.38 | 2024 | Cequr Simplicity |
| Acella Pharmaceuticals, LLC | $20.22 | 2024 | NP Thyroid 60 |
| Alvogen INC | $20.00 | 2023 | Teriparatide |
| Ascensia Diabetes Care US INC. | $17.89 | 2023 | |
| Astellas Pharma US INC | $17.42 | 2024 | Veozah |
| Tolmar, INC. | $15.38 | 2024 | |
| Nevro Corp. | $14.94 | 2023 | Senza |
| Currax Pharmaceuticals LLC | $13.71 | 2024 | Contrave |
| Eusa Pharma (US) LLC | $13.38 | 2022 | |
| Recordati_rare_diseases_inc. | $13.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mallory Searcy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.